

LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCES CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER

FINANCIAL STATEMENTS AND REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

June 30, 2007

Under provisions of state law, this report is a public document. A copy of the report has been submitted to the entity and other appropriate public officials. The report is available for public inspection at the Baton Rouge office of the Legislative Auditor and, where appropriate, at the office of the parish clerk of court.

Release Date 10 31 07

TABLE OF CONTENTS

<u>. </u>	age'
FINANCIAL SECTION	
Independent Auditor's Report	1
Statement of Financial Position	3
Statement of Activities	4
Statement of Cash Flows	5
Notes to Financial Statements	6
SUPPLEMENTAL INFORMATION	,
Schedule of Revenues and Expenses by Program	13
REPORTS REQUIRED BY GOVERNMENT AUDITING STANDARDS	
Independent Auditor's Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of the Financial Statements Performed in Accordance with	
Government Auditing Standards	
Schedule of Findings and Questioned Costs	16
Summary Schedule of Prior Audit Findings	17
Corrective Action Plan	18
OTHER SUPPLEMENTARY INFORMATION REQUIRED BY THE STATE OF LOUISIANA	20

FINANCIAL SECTION

REBOWE & COMPANY

CERTIFIED PUBLIC ACCOUNTANTS CONSULTANTS

A PROFESSIONAL CORPORATION

3501 N. Causeway Blvd. • Suite 810 • P.O. Box 6952 • Metairie, LA 70009 Phone (504) 837-9116 • Fax (504) 837-0123 • E-mail rebowe@rebowe.com

INDEPENDENT AUDITOR'S REPORT

Board of Directors

Louisiana Cancer Research Center of L.S.U. Health Sciences Center in

New Orleans/Tulane Health Sciences Center

New Orleans, Louisiana

We have audited the accompanying Statement of Financial Position of Louisiana Cancer Research Center of L.S.U Health Sciences Center in New Orleans/Tulane Health Sciences Center (a non-profit organization) (the "Center") as of June 30, 2007 and the related Statements of Activities and Cash Flows for the year then ended. These financial statements are the responsibility of the Center's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Louisiana Cancer Research Center of L.S.U. Health Sciences Center in New Orleans/Tulane Health Sciences Center as of June 30, 2007 and the changes in its net assets and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

In accordance with Government Auditing Standards, we have also issued our report dated August 31, 2007 on our consideration of Louisiana Cancer Research Center of L.S.U. Health Sciences Center in New Orleans/Tulane Health Sciences Center's internal control over financial reporting and our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the internal control over financial reporting or on compliance. The

report is an integral part of an audit performed in accordance with Government Auditing Standards and should be considered in assessing the results of our audit.

Our audit was performed for the purpose of forming an opinion on the basic financial statements of Louisiana Cancer Research Center of L.S.U. Health Sciences Center in New Orleans/Tulane Health Sciences Center taken as a whole. The accompanying combining Statement of Activities and the other supplementary information required by the State of Louisiana is presented for purposes of additional analysis and is not a required part of the basic financial statements. Such information has been subjected to the auditing procedures applied in the audit of the basic financial statements and, in our opinion, is fairly stated, in all material respects, in relation to the basic financial statements taken as a whole.

Rebowe & Company

August 31, 2007

LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCES CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER STATEMENT OF FINANCIAL POSITION

June 30, 2007 (with comparative totals for 2006)

·				
		2007		2006
AS	SETS			
Current Assets				
Cash	. \$	22,743,310	\$	16,517,899
Investments	,	10,321,226	·	-
Receivables		•		-
Grants		4,602,891		16,763,385
Other		663,840		52,561
Total Current Assets		38,331,267		33,333,845
Property and equipment - net		6,295,842		5,417,533
Total Assets	\$	44,627,109	\$	38,751,378
LIABILITIES A	AND NET	T ASSETS		
Current Liabilities				
Accounts payable	\$	3,928,010	\$	1,808,188
Accrued liabilities	 ,**	40,985		24,935
Total Current Liabilities		3,968,995	·	1,833,123
Net Assets				
Unrestricted		234,056		160,191
Temporarily restricted		40,424,058		36,758,064
Total Net Assets		40,658,114		36,918,255
Total Liabilities and Net Assets	\$	44,627,109	\$	38,751,378

See accompanying notes to the financial statements.

LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCES CENTER

IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER STATEMENT OF ACTIVITIES

For the Year Ended June 30, 2007 (with comparative totals for 2006)

•		Temporarily	Tot	als	
	Unrestricted	Restricted	2007	2006	
OPERATING REVENUE		-			
Grants	\$ -	\$ 18,411,563	\$ 18,411,563	\$ 16,763,385	
Interest	-	846,931	846,931	331,647	
Fund raising	68,090		68,090	152,250	
Other	5,775	-	5,775	5,249	
Net assets released					
from restrictions	15,913,726	(15,913,726)	_	-	
Total	15,987,591	3,344,768	19,332,359	17,252,531	
OPERATING EXPENSES				•	
Salaries and related expenses	4,333,418	-	4,333,418	4,055,458	
Professional services	132,591	-	132,591	144,143	
Operating services	241,566	-	241,566	128,240	
Supplies	2,540,802	-	2,540,802	1,422,131	
Travel	220,683	•	220,683	57,323	
Marketing	50,621	-	50,621	8,142	
Business expenses	11,110	-	11,110	11,074	
Other expenses	23,187	•	23,187	6,777	
Fund raising expenses	169,206	-	169,206	32,845	
Depreciation	431,834		431,834	402,983	
Cessation expenses	7,758,708	_	7,758,708	7,768,441	
Total	15,913,726		15,913,726	14,037,557	
OPERATING INCOME	73,865	3,344,768	3,418,633	3,214,974	
NONOPERATING REVENUES					
Investment income	-	306,171	306,171	-	
Net change in unrealized		•			
gain on investments		15,055	15,055		
Total		321,226	321,226		
INCREASE IN NET ASSETS	73,865	3,665,994	3,739,859	3,214,974	
Net Assets, Beginning of Year	160,191	36,758,064	36,918,255	33,703,281	
Net Assets, End of Year	\$ 234,056	\$ 40,424,058	\$ 40,658,114	\$ 36,918,255	

See accompanying notes to the financial statements.

LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCES CENTER

IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER STATEMENT OF CASH FLOWS

For the Year Ended June 30, 2007

(with comparative totals for 2006)

	2007	2006
CASH FLOWS FROM OPERATING ACTIVITIES		
Grant revenue	\$ 30,572,057	\$ 17,850,000
Interest income	846,931	331,648
Other income	73,865	105,044
	31,492,853	18 ,286,6 92
Payments to employees and suppliers and		
for research expenses	(13,957,299)	(14,349,859)
Net Cash Provided by (Used in) Operating Activities	17,535,554	3,936,833
CASH FLOWS FROM INVESTING ACTIVITIES		
Acquisition of property and equipment	(1,310,143)	(832,258)
Investment income	306,171	
Purchase of investments	(10,306,171)	
Net Cash Provided by (Used in) Investing Activities	(11,310,143)	(832,258)
Net Increase in Cash and Cash Equivalents	6,225,411	3,104,575
Cash and Cash Equivalents at Beginning of Year	16,517,899	13,413,324
Cash and Cash Equivalents at End of Year	\$ 22,743,310	\$ 16,517,899
RECONCILIATION OF INCREASE IN NET ASSETS TO NET CASH PROVIDED BY OPERATING ACTIVITIES		
Operating income	\$ 3,418,633	\$ 3,214,974
Adjustments to Reconcile Increase in Net Assets Provided by Operating Activities:		
Depreciation	431,834	402,983
(Increase) Decrease in Operating Assets:	,2 1,02 1	.02,500
Receivables	11,549,215	1,034,054
Contractual services advance	,	320,982
Increase (Decrease) in Operating Liabilities:		•
Accounts payable	2,135,872	(1,036,160)
Total Adjustments	14,116,921	721,859
NET CASH PROVIDED BY OPERATING		
ACTIVITIES	\$ 17,535,554	\$ 3,936,833

See accompanying notes to the financial statements.

NOTE A - SUMMARY OF ACCOUNTING POLICIES

A summary of the Center's significant accounting policies consistently applied in the preparation of the accompanying financial statements follows:

Nature of Activities

Louisiana Cancer Research Center of L.S.U. Health Sciences Center in New Orleans/Tulane Health Sciences Center (the "Center") was incorporated June 7, 2002 under the laws of the State of Louisiana. The Center is a not-for-profit organization that is exempt from income taxes under Section 501 (c) (3) of the Internal Revenue Code, and qualifies as an organization that is not a private foundation as defined in Section 509(a) of the Code. It is exempt from Louisiana income tax under the authority of R.S. 47:121(5).

The Center was organized for charitable, educational and scientific purposes. The primary purpose will be to conduct and support research and promote education in the diagnosis, detection, and treatment of cancer in the pursuit of obtaining the National Cancer Institute designation for its members, the Louisiana State University Health Sciences Center in New Orleans, and the Tulane University Health Sciences Center.

Financial Statement Presentation

The Center's financial statements are presented in accordance with the requirements established by the Financial Accounting Standards Board (FASB) as set forth in the Statement of Financial Accounting Standards No. 117, "Financial Statements of Not-For-Profit Organizations." Accordingly, the net assets of the Center are reported in each of the following classes: (a) unrestricted net assets, (b) temporarily restricted net assets, and (c) permanently restricted net assets. There were no permanently restricted net assets during the year ended June 30, 2007.

Basis of Accounting

The financial statements of the Center are prepared on the accrual basis of accounting.

Reporting Entity

Using the criteria established in GASB Statement No. 14, The Financial Reporting Entity as amended by GASB Statement No. 39, Determining Whether Certain Organizations are Component Units, the Center is reported as a discretely presented component unit of the State of Louisiana since it is legally separate from and is financially accountable to the State of Louisiana.

NOTE A - SUMMARY OF ACCOUNTING POLICIES (CONTINUED)

Annually, the State of Louisiana issues a comprehensive financial report, which includes the activity contained in the accompanying financial statements. The Louisiana Legislative Auditor audits the basic financial statements of the State of Louisiana.

Revenue Recognition

For financial reporting purposes, the Center recognizes all contributed support as income in the period received. Contributed support is reported as unrestricted or restricted depending on the existence of donor stipulations that limit the use of the support. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the Statement of Activities as "net assets released from restrictions."

Grant revenue is recognized as it is earned in accordance with approved contracts.

Expense Allocation

The costs of providing various programs and other activities are summarized on a functional basis in the financial statements. Accordingly, certain costs are allocated among the programs and supporting services benefited.

Cash and Cash Equivalents

Cash consists of deposits with financial institutions, including savings and demand deposits. These deposits are stated at cost, which approximates market.

For the purposes of the Statement of Cash Flows, the Center considers all investments with original maturities of three months or less to be cash equivalents.

Investments

The Center accounts for investments under Statement of Financial Accounting Standards (SFAS) No. 124, Accounting for Certain Investments Held by Not for-Profit Organizations. Under SFAS No. 124, investments in equity securities with readily determinable fair values and all investments in debt securities are reported at their fair values in the Statements of Financial Position. For valuation purposes, fair value is measured using quoted prices in active markets.

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

NOTE A - SUMMARY OF ACCOUNTING POLICIES (CONTINUED)

Property and equipment

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided for in amounts sufficient to relate the costs of depreciable assets to operations over their estimated service lives, on a straight-line basis. It is the policy of the Center to capitalize property and equipment with an acquisition cost in excess of \$5,000.

Comparative Financial Information

The financial statements include certain prior-year summarized comparative information in total but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with generally accepted accounting principles. Accordingly, such information should be read in conjunction with the Center's financial statements for the year ended June 30, 2006 from which the summarized information was derived.

<u>Reclassifications</u>

Certain amounts from 2006 have been reclassified to conform to the 2007 financial presentation.

NOTE B - CASH

Cash includes \$22,713,413 of repurchase agreements. The repurchase agreements are secured by U.S. Treasury obligations.

At June 30, 2007, the bank balance of the Center's cash was \$559,154 of which \$174,058 was covered by federal depository insurance and the remainder was collateralized by securities in the Center's name held by the Federal Reserve Bank with market values totaling \$709,603.

NOTE C - INVESTMENTS

At June 30 2007, investments consist of the following:

MANUFACTOR OF CONTROL OF COOK	M	larketa	ble	securities,	at	cost:
-------------------------------	---	---------	-----	-------------	----	-------

Short-term instruments \$ 5,825,926 U.S. Government securities 4,480,245 Net unrealized gain on marketable

securities _____15,055

Investments, at market \$\frac{\$\ 10.321.226}{}

NOTE C - INVESTMENTS (CONTINUED)

The investment management fees are netted against investment income. For the fiscal year ended June 30, 2007, \$128,818 in investment management fees was netted against investment income.

NOTE D - GRANTS RECEIVABLE AND REVENUE

Grant revenue consists of the following at June 30, 2007:	Receivable	Revenue
Louisiana State University Health Sciences Center in New Orleans - Cancer Research	\$ 2,736,163	\$10,944,652
Louisiana State University Health Sciences Center in New Orleans - Cessation Program	1,866,728	7,466,911
	<u>\$4,602,891</u>	<u>\$18.411,563</u>

NOTE E - PROPERTY AND EQUIPMENT

Property and equipment consists of the following at June 30, 2007:

Research equipment	\$ 3,698,373
Office equipment	<u>57,108</u>
	3,755,481
Less accumulated depreciation	<u>(1,019,282)</u>
	2,736,199
Land	671,808
Construction in progress - building	<u> 2,887,835</u>
	<u>\$ 6,295,842</u>

Cancer research is currently being performed at Louisiana State University Health Sciences Center and Tulane Health Sciences Center. Construction of a combined cancer research facility was estimated to begin in October 2006 at an estimated construction cost of \$46 million but due to Hurricane Katrina, the project has been delayed. The project will commence in February 2008, however, estimated construction costs have increased to \$92 million. Construction in progress as of June 30, 2007 relates to pre-construction costs. Each of the separate university cancer centers will occupy the new facility when completed.

Depreciation expense for the year ended June 30, 2007 totaled \$431,834.

NOTE F - RETIREMENT PLAN

All full-time Louisiana Cancer Research Center employees are eligible to participate in the 403(b) retirement plan. The existing 403(b) plan is a tax-sheltered annuity (TSA) plan, currently administered by TIAA-CREF. Although eligible employees are not required to participate in the Plan, contributions are made by the Center as part of the established benefits package. The Plan also allows for employee contributions with a matching requirement up to 3% of the employee's annual compensation. The Center contributed \$32,252 to the Plan for the year ended June 30, 2007.

NOTE G - SCHEDULE OF FUNCTIONAL EXPENSES

A Schedule of Functional Expenses for the year ended June 30, 2007 is as follows:

Program Expenses		General and Administration	Fund <u>Raising</u>	Total	
Salaries and related expenses	\$ -	\$ 267,987	\$ -	\$ 267,987	
Professional services	-	62,615	-	62,615	
Operating services	-	210,087	-	210,087	
Supplies	-	143,399	-	143,399	
Travel	-	4,530	-	4,530	
Research expenses	6,842,173	-	-	6,842,173	
Cessation expenses	7,758,708	-	-	7,758,708	
Depreciation	-	431,834	-	431,834	
Other expenses	-	23,187	-	23,187	
Fund raising expenses			<u>169,206</u>	169,206	
	\$14,600,881	\$ 1,143,639	\$ 169,206	<u>\$ 15,913,726</u>	

NOTE H - BOARD OF DIRECTORS' COMPENSATION

The Board of Directors is a voluntary board. Accordingly, no compensation was paid to any board member during the year ended June 30, 2007.

NOTE I - ECONOMIC DEPENDENCY

The Center received ninety-four percent of its revenue from funds provided through grants administered by the State of Louisiana during the year ended June 30, 2007. The grant amounts are appropriated annually by the State of Louisiana. If significant budget cuts to the Center are made at the State level, the amount of funds the Center receives could be reduced significantly and have an adverse impact on its operations.

NOTE J - RELATED PARTIES

Louisiana Gene Therapy Research Consortium

The Louisiana Cancer Research Center of LSU Health Sciences Center in New Orleans/Tulane Health Sciences Center (the "Center") and the Louisiana Gene Therapy Research Center (LGTRC) have an affiliate relationship as they are both partnerships between the LSU Health Sciences Center in New Orleans and the Tulane Health Sciences Center. LGTRC includes both LSU Health Sciences Center in New Orleans and in Shreveport and Tulane Health Sciences Center as partners while the Center includes only L.S.U. Health Sciences Center in New Orleans and Tulane University Health Sciences Center, which are governed by governing boards with common members.

The Center has an arrangement with the LGTRC that allows for resource cost sharing. The Center and LGTRC share office space, personnel, and other related supplies and services. Overhead expenses are captured in a cost (common cost) pool and allocated to the appropriate organization based on space, usage, and "percent of effort" where applicable. LGTRC pays all shared expenses on behalf of the Center's research and cessation components. The Center reimburses LGTRC based on billings. The total billed to the Center for the fiscal year ended June 30, 2007 was \$384,038.

LSU Health Sciences Center in New Orleans

LSU Health Sciences Center in New Orleans is one of the two partner institutions that comprise the Center. The other institution is Tulane University Health Sciences Center.

As management, two members of the LSU Health Sciences Center in New Orleans are on the governing board of the Center. The Chancellor of LSU Health Sciences Center in New Orleans is currently the Chair of the Center (the position rotates annually between the Chancellor of LSU Health Sciences Center and the Senior Vice President for Tulane Health Sciences Center, as dictated by statute). The Senior Vice President for Tulane Health Sciences Center was chair for fiscal year 2007. The Vice Chancellor for Academic Affairs of LSU Health Sciences Center in New Orleans is also a voting member of the Center's Board.

As transferring agent of state funding support, LSU Health Sciences Center in New Orleans (an entity of the State) is the transferring agency on behalf of the State. Under a Cooperative Endeavor Agreement arrangement, it is responsible for transferring funds appropriated by the State of Louisiana for the Center.

As grantee, the LSU Health Sciences Center in New Orleans is allocated the Center funding support for program development (part of the mission of the Center). Transfer of funds to LSU Health Sciences Center in New Orleans for the program is governed by a fully executed operating agreement which includes an annual budget submitted by LSU Health Sciences Center

NOTE J - RELATED PARTIES (CONTINUED)

in New Orleans and approved by the Center's Board. The total amount billed to the Center for services rendered during the fiscal year ended June 30, 2007 was \$3,706,402.

As a vendor, LSU Health Sciences Center Auxiliary Stores provide goods and services (including research equipment, office and computer supplies) to the Center. The stores conveniently provide products and services which support the mission of the Center. The total amount billed to the Center for goods and services during the fiscal year ended June 30, 2007 was \$131,926.

Tulane University Health Sciences Center

Tulane University Health Sciences Center (TUHSC) is one of the two partner institutions that comprise the Center. The other institution is LSU Health Sciences Center in New Orleans.

As management, two members of the Tulane University Health Sciences Center are on the governing board of the Center. TUHSC's Senior Vice President (currently Vice-Chair of the Center) and Associate Senior Vice President for Health Sciences are voting members of the Center's Board.

Tulane University Health Sciences Center (Continued)

As grantee, TUHSC is allocated Center funding support for program development (part of the mission of the Center). Transfer of funds to TUHSC for the program is governed by a fully executed operating agreement which includes an annual budget submitted by TUHSC and approved by the Center's Board. The total amount billed to the Center for services rendered during the fiscal year ended June 30, 2007 was \$4,150,489.

SUPPLEMENTAL INFORMATION

LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCES CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER SCHEDULE OF REVENUES AND EXPENSES BY PROGRAM For the Year Ended June 30, 2007

	Cancer Research	Cessation	Fund Raising	Property and Equipment	Total
REVENUE					
Grants	\$ 10,944,652	\$ 7,466,911	\$ -	\$ -	\$ 18,411,563
Interest	707,315	132,425	7,191	•	846,931
Investment income	306,171	•	-	-	306,171
Net change in unrealized					
gain on investments	15,055	•	-	-	15,055
Other	5,775		68,090	-	73,865
Total Revenue	11,978,968	7,599,336	75,281	•	19,653,585
EXPENSES					
Salaries and related					
expenses	267,987	-	•	•	267,987
Professional services	62,615	•	•	-	62,615
Operating services	210,087	-	-	•	210,087
Supplies	143,399	•	-	•	143,399
Travel	4,530	-	-	•	4,530
Research expenses	6,842,173	-	-	-	6,842,173
Cessation expenses	•	7,758,708	•	-	7,758,708
Depreciation	•	•	-	431,834	431,834
Other expenses	23,187	-	-	-	23,187
Fund raising expenses	-		<u>169,206</u>		169,206
Total Expenses	7,553,978	7,758,708	169,206	431,834	15,913,726
INCREASE (DECREASE) IN					
NET ASSETS	4,424,990	(159,372)	(93,925)	(431,834)	3,739,859
Property and Equipment					
Capital ized	(1,310,143)	-	-	1,310,143	•
NET ASSETS,					
BEGINNING OF YEAR	21,307,968	10,066,181	126,573	5,417,533	36,918,255
NET ASSETS,					
END OF YEAR	\$ 24,422,815	\$ 9,906,809	\$ 32,648	\$ 6,295,842	\$ 40,658,114



REBOWE & COMPANY

CERTIFIED PUBLIC ACCOUNTANTS CONSULTANTS

A PROFESSIONAL CORPORATION

3501 N. Causeway Blvd. • Suite 810 • P.O. Box 6952 • Metairie, LA 70009 Phone (504) 837-9116 • Fax (504) 837-0123 • E-mail rebowe@rebowe.com

INDEPENDENT AUDITOR'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

Board of Directors

Louisiana Cancer Research Center of L.S.U. Health Sciences Center
in New Orleans/Tulane Health Sciences Center
New Orleans, Louisiana

We have audited the financial statements of Louisiana Cancer Research Center of L.S.U. Health Sciences Center in New Orleans/Tulane Health Sciences Center (a non-profit organization), as of and for the year ended June 30, 2007, and have issued our report thereon dated August 31, 2007. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States.

Internal Control Over Financial Reporting

In planning and performing our audit, we considered the Louisiana Cancer Research Center internal control over financial reporting as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion of the effectiveness of the Louisiana Cancer Research Center internal control over financial reporting. Accordingly, we do not express an opinion on the effectiveness of the Louisiana Cancer Research Center internal control over financial reporting.

A control deficiency exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A significant deficiency is a control deficiency, or combination of control deficiencies, that adversely affects the entity's ability to initiate, authorize, record, process, or report financial data reliably in accordance with generally accepted accounting principles such that there is more than a remote likelihood that a misstatement of the Louisiana Cancer Research Center financial statements that is more than inconsequential will not be prevented or detected by the Louisiana Cancer Research Center internal control.

A material weakness is a significant deficiency, or combination of significant deficiencies, that results in more than a remote likelihood that a material misstatement of the financial statements will not be prevented or detected by the Louisiana Cancer Research Center's internal control.

Our consideration of internal control over financial reporting was for the limited purpose described in the first paragraph of this section and would not necessarily identify all deficiencies in internal control that might be significant deficiencies or material weaknesses. We did not identify any deficiencies in internal control over financial reporting that we consider to be material weaknesses, as defined above.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether Louisiana Cancer Research Center of L.S.U. Health Sciences Center in New Orleans/Tulane Health Sciences Center's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under Government Auditing Standards.

This report is intended solely for the information and use of the Audit Committee, management, others within the Center, Louisiana awarding agencies, Louisiana Legislative Auditor, and it is not intended to be and should not be used by anyone other than these specified parties. Under Louisiana Revised Statute 24:513, this report is distributed by the Legislative Auditor as a public document.

Rebowe & Company

August 31, 2007

LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCES CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER SCHEDULE OF FINDINGS AND QUESTIONED COSTS Year Ended June 30, 2007

A. Summary of Auditor's Results

- 1. The auditor's report expresses an unqualified opinion on the financial statements of the Louisiana Cancer Research Center of L.S.U. Health Sciences Center in New Orleans/Tulane Health Sciences Center.
- 2. No significant deficiencies relating to the audit of the financial statements are reported in the Independent Auditor's Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards.
- 3. No instances of noncompliance material to the financial statements of the Louisiana Cancer Research Center of L.S.U. Health Sciences Center in New Orleans/Tulane Health Sciences Center, which would be required to be reported in accordance with *Government Auditing Standards*, were disclosed during the audit.
- 4. A Management Letter was not issued for the year ended June 30, 2007.

B. Findings - Financial Statement Audit

There were no findings for the current year.

LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCES CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS For the Year Ended June 30, 2007

A. Findings - Financial Statement Audit

There were no findings for the year ended June 30, 2006.

B. Management Letter

A Management Letter was not issued for the year ended June 30, 2006.

LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCES CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER CORRECTIVE ACTION PLAN June 30, 2007

There are no compliance and/or internal control findings as described in the Schedule of Findings and Questioned Costs. Accordingly, there is no corrective action plan required as part of this section.

OTHER SUPPLEMENTARY INFORMATION REQUIRED BY THE STATE OF LOUISIANA

Louisiana Cancer Research Center STATE OF LOUISIANA Annual Financial Statements June 30, 2007

CONTENTS

TRANSMITTAL LETTER AFFIDAVIT

		Statements 5 4 1
MD&A		
Balance Shee	et	A
Statement of	Revenues, Expenses, and Changes in Fund Net Assets	В
Statement of	Activities	С
Statement of	Cash Flows	D
Notes to the I	Financial Statements	
A.	Summary of Significant Accounting Policies	
В.	Budgetary Accounting	
C.	Deposits with Financial Institutions and Investments (Information in Ap	pendix B)
D.	Capital Assets – Including Capital Lease Assets	• • • • • •
E,	Inventories	
F.	Restricted Assets	
G.	Leave	
H.	Retirement System	
l,	Post Retirement Health Care and Life Insurance Benefits	
J.	Leases	
K.	Long-Term Liabilities	
Ĺ.	Contingent Liabilities	
М.	Related Party Transactions	
N.	Accounting Changes	
Ο.	In-Kind Contributions	
P.	Defeased Issues	
Q.	Cooperative Endeavors (moved to Schedule 16)	
R.	Government-Mandated Nonexchange Transactions (Grants)	
S.	Violations of Finance-Related Legal or Contractual Provisions	
T.	Short-Term Debt	
U.	Disaggregation of Receivable Balances	
V.	Disaggregation of Payable Balances	
W.	Subsequent Events	
X.	Segment Information	
Y.	Due to/Due from and Transfers	
Z.	Liabilities Payable from Restricted Assets	
AA.	Prior-Year Restatement of Net Assets	
BB.	Net Assets Restricted by Enabling Legislation (Information in Appendit	x C)
CC.	Impairment of Capital Assets (Information in Appendix D)	
DD.	Employee Termination Benefits	
Schedules		
1	Schedule of Per Diem Paid to Board Members	
2	Not Applicable	
3	Schedules of Long-Term Debt	
4	Schedules of Long-Term Debt Amortization	
15	Schedule of Comparison Figures and Instructions	
16	Schedule of Cooperative Endeavors	

Schedule Number

STATE OF LOUISIANA Annual Financial Statements Fiscal Year Ending June 30, 2007

LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCES CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER.

Division of Administration Office of Statewide Reporting and Accounting Policy P. O. Box 94095 Baton Rouge, Louisiana 70804-9095 Legislative Auditor P. O. Box 94397 Baton Rouge, Louisiana 70804-9397

Physical Address: 1201 N. Third Street

Claiborne Building, 6th Floor, Suite 6-130 Baton Rouge, Louisiana 70802

Physical Address: 1600 N. Third Street Baton Rouge, Louislana 70802

AFFIDAVIT

Personally came and appeared before the undersigned authority. Deborah C. Reeder, Vice President of Finance of the Louistana Cancer Research Center of L.S.U. Health Sciences Center in New Orleans/Tulane Health Sciences Center who duly swom, deposes and says, that the financial statements herewith given present fairly the financial position of Louisiana Cancer Research Center of Health Sciences Center in New Orleans/Tulane Health Sciences at June 30, 2007 and the results of operations for the year then ended in accordance with policies and practices established by the Division of Administration or in accordance with Generally Accepted Accounting Principles as prescribed by the Governmental Accounting Standards Board. Sworn and subscribed before me, this

Signature of Agency Official

Prepared by: Ryan Graffagnini

Title: Fiscal Operations Analyst

Telephone No.: (504) 598 1557

Date: 8/29/07


The Management's Discussion and Analysis of the <u>Louisiana Cancer Research Center of L.S.U. Health Sciences Center in New Orleans/Tulane Health Sciences Center</u> (Louisiana Cancer Research Center's) financial performance presents a narrative overview and analysis of the Louisiana Cancer Research Center's financial activities for the year ended June 30, 2007. This document focuses on the current year's activities, resulting changes, and currently known facts in comparison with the prior year's information. Please read this document in conjunction with the additional information contained in the Louisiana Cancer Research Center's financial statements, which begin on page 27.

FINANCIAL HIGHLIGHTS

- ★ The Louisiana Cancer Research Center's assets exceeded its liabilities at the close of fiscal year 2007 by \$40,658,114 which represents a 10% increase over last fiscal year. The total net assets increased by \$3,739,859 (or 10%) which indicates an improving financial position.
- ★ The Louisiana Cancer Research Center's total revenue increased by \$2,401,054 (or 14%) and the net results from activities increased by \$524,885 (or 16%) compared to last year's net results.
- ★ The 10% increase in total revenue for fiscal year ended June 30, 2007 is attributable to the State's revenue estimating committee's (REC) projection and the actual realization of tobacco tax receipts for fiscal year ending June 30, 2007. The Louisiana Cancer Research Center also experience an \$821,455 (or 248%) increase in interest and investment income.
- * The 16% increase in net results from activities is attributable to the increase in income which includes tobacco tax collections (state grant revenue) and interest earnings on investments, offset by a modest 13% increase in expenses as compared to last year's.

OVERVIEW OF THE FINANCIAL STATEMENTS

The following graphic illustrates the minimum requirements for Special Purpose Governments Engaged in Business-Type Activities established by Governmental Accounting Standards Board Statement 34, Basic Financial Statements—and Management's Discussion and Analysis—for State and Local Governments.



These financial statements consist of three sections - Management's Discussion and Analysis (this section), the Basic Financial Statements (including the notes to the financial statements), and Required Supplementary Information.

Basic Financial Statements

The basic financial statements present information for the Louisiana Cancer Research Center as a whole, in a format designed to make the statements easier for the reader to understand. The statements in this section include the Balance Sheet; the Statement of Revenues, Expenses, and Changes in Fund Net Assets; and the Statement of Cash Flows.

The <u>Balance Sheet</u> (page 28) presents the current and long-term portions of assets and liabilities separately. The difference between total assets and total liabilities is net assets and may provide a useful indicator of whether the financial position of the Louisiana Cancer Research Center is improving or deteriorating.

The <u>Statement of Revenues</u>, <u>Expenses</u>, <u>and Changes in Fund Net Assets</u> (page 29 - 30) presents information showing how the Louisiana Cancer Research Center's assets changed as a result of current year operations. Regardless of when cash is affected, all changes in net assets are reported when the underlying transactions occur. As a result, there are transactions included that will not affect cash until future fiscal periods.

The <u>Statement of Cash Flows</u> (pages 31 - 32) presents information showing how Louisiana Cancer Research Center's cash changed as a result of current year operations. The cash flow statement is prepared using the direct method and includes the reconciliation of operating income(loss) to net cash provided(used) by operating activities (indirect method) as required by GASB 34.

FINANCIAL ANALYSIS OF THE ENTITY

Statement of Net Assets as of June 30, 2007 (in thousands)

	Total			
		2007		2006
Current and other assets	\$	38,331	\$	33,334
Capital assets		6,296		5,418
Total assets		44,627		38,752
Other liabilities		3,969	_	1,808
Long-term debt outstanding		•		•
Total liabilities		3,969		1,833
Net assets:				
Invested in capital assets, net of debt				
Restricted		39,256		36,758
Unrestricted		1,402		160
Total net assets	\$	40,658	\$	36,918

Restricted net assets represent those assets that are not available for spending as a result of legislative requirements, donor agreements, or grant requirements. Conversely, unrestricted net assets are those that do not have any limitations on how these amounts may be spent.

Net assets of the Louisiana Cancer Research Center increased by \$3,739,859 or (10%), from June 30, 2006 to June 30, 2007. The primary cause of this increase is the excess of revenues over expenditures for this period.

Statement of Revenues, Expenses, and Changes in Fund Net Assets for the years ended June 30, 2007 (in thousands)

	Total			
		2007		2006
Operating revenues Operating expenses	\$	19,332 15,913	\$ 	16,763 14,038
Operating income(loss)	~~~	3,419		2,725
Non-operating revenues(expenses)		321		489
Income(loss) before transfers		3,740		3,214
Transfers in Transfers out	_			
Net increase(decrease) in net assets	\$	3,740	\$	3,214

The Louisiana Cancer Research Center's total revenues increased by \$2,401,054 or (14%). The total cost of all programs and services increased by \$1,876,169 (or 13%). The increase in total cost of all programs is attributable to increased program activities, specifically in the area of cancer research. Supply costs increased by \$1,118,671 or (79%) due to the expansion and continuation of cancer research activity. Research and Cessation Program expenses are expected to increase significantly as both programs continue to expand. The fiscal year ending June 30, 2007 represents the fourth (4th) full year of operation for the Louisiana Cancer Research Center.

CAPITAL ASSET AND DEBT ADMINISTRATION

Capital Assets

At the end of 2007, the Louisiana Cancer Research Center had \$6,295,842 invested in a broad range of capital assets, including research and office equipment (net), construction in progress and land for the construction of a state of the art cancer research facility. (See Following Table)

This amount represents a net increase of \$878,309, (or 16%), over last year.

	2007		2006	
Land	\$	672	\$	672
Buildings and improvements		2,888		2,410
Equipment Infrastructure	to the state of th	2,736		2,335
	Totals \$	6,296	\$	5,417

This year's major additions included (in thousands):

- Research Equipment \$833
- Construction in progress \$478

Debt

The Louisiana Cancer Research Center had \$3,928,010 in accounts payable at year-end. Other obligations include accrued leave at \$40,985. The Louisiana Cancer Research Center had no long-term debt at year end.

VARIATIONS BETWEEN ORIGINAL AND FINAL BUDGETS

Revenues realized were consistent with budget while expenditures were approximately 16% less than budget due in part to continuous difficulty in recruiting faculty and researchers, post-Katrina.

ECONOMIC FACTORS AND NEXT YEAR'S BUDGETS AND RATES

The Louisiana Cancer Research Center elected and appointed officials considered the following factors and indicators when setting next year's budget, rates, and fees. These factors and indicators include:

- Strategic and operational needs assessments for programs and building construction is a work in progress
- Recruitment and retention of world class faculty more difficult yet more critical in to the success
 of the Center, thus requiring increased investment in programs
- Meaningful and significant reductions in the number of smoking related deaths and illnesses will
 require substantial investment in the smoking cessation program

The Louisiana Cancer Research Center expects that next year's results will improve based on the following:

- State supplemental appropriations for the construction of the Cancer Center are expected to be approved and made available within fiscal year 2008
- · Short-term investment interest earnings are expected to increase
- Program development activities including faculty recruitment should improve thus resulting in an increase in the number of NIH/NCI funded faculty and an increase in federal grants which can be used to support further program development
- The Cancer Center building needs assessment and operations plan will be completed and will result in a new and aggressive plan and timeline for construction and operation of the Cancer Center building

CONTACTING THE LOUISIANA CANCER RESEARCH CENTER'S MANAGEMENT

This financial report is designed to provide our citizens, taxpayers, customers, and investors and creditors with a general overview of the Louisiana Cancer Research Center's finances and to show the Louisiana Cancer Research Center's accountability for the money it receives. If you have questions about this report or need additional financial information, contact Deborah Reeder at (504)598-1557.

STATE OF LOUISIANA LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCE CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER BALANCE SHEET AS OF JUNE 30, 2007

ASSETS	
CURRENT	ASSETS:

	Cash and cash equivalents	\$	22.743.310
	Investments		10,321,226
	Receivables (net of allowance for doubtful accounts)(Note U)		5,266,732
	Due from other funds (Note Y)		
	Due from federal government		
	Inventories		**************************************
	Prepayments		
	Notes receivable		-
	Other current assets		******
HONOUDDEN	Total current assets		38,331,268
NONCURREN'			
	Restricted assets (Note F):		
	Cash		•
	Investments		
	Receivables		
	Notes receivable		
	Investments		
	Capital assets (net of depreciation)(Note D)		074 000
	Land		<u>671,808</u>
	Buildings and improvements		
	Machinery and equipment		2,736,199
	Infrastructure		
	Construction in progress		2,887,835
	Other noncurrent assets		
			6,295,842
	Total noncurrent assets		
	Total assets	Þ	44.627.110
LIABILITIES			
CURRENT LIA	BILITIES:		
	Accounts payable and accruals (Note V)	\$	3,968,995
	Due to other funds (Note Y)	•	
	Due to federal government		
	Deferred revenues		
			
	Amounts held in custody for others		
	Other current liabilities		
	Current portion of long-term liabilities:		
	Contracts payable		
	Compensated absences payable (Note K)		
	Capital lease obligations - (Note J)		
	Claims and litigation payable (Note K)		
	Notes payable		
			
	Liabilities payable from restricted assets (Note Z)		
	Bonds payable		
	Other long-term liabilities		
	Total current liabilities		3,968,995
NON-CURREN	T LIABILITIES:		
	Contracts payable		
	Compensated absences payable (Note K)		
	Claims and litigation payable (Note K)		
	Notes pavable		
	Liabilities payable from restricted assets (Note Z)		
	Bonds payable		
	Other long-term liabilities		
	AMA - 1.2" 1 11 1.444.4		
	Total long-term liabilities		2 000 000
	Total liabilities		3,968,995
NET ASSETS			* ** · · ·
	Invested in capital assets, net of related debt		6,295,842
	Restricted for:		
	Capital projects		
	Debt service		
	Dent settice		
	Unemployment compensation		
	Unemployment compensation Other specific purposes		24 282 277
	Unemployment compensation Other specific purposes Unrestricted		34,362,273 40,659,445
	Unemployment compensation Other specific purposes		34,362,273 40,658,115 44,627,110

The accompanying notes are an integral part of this financial statement.

STATE OF LOUISIANA LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCE CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER STATEMENT OF REVENUES, EXPENSES, AND CHANGES IN FUND NET ASSETS FOR THE YEAR ENDED JUNE 30, 2007

OPERATING REVENUES	
Sales of commodities and services	\$
Assessments	
Use of money and property	
Licenses, permits, and fees	
Other - Grants (LSU HSC)	18,411,563
Other - Fundraising	68,090
Total operating revenues	18,479,653
OPERATING EXPENSES	
Cost of sales and services	
Administrative	15,481,892
Depreciation	431,834
Amortization	
Total operating expenses	15,913,726
Operating income(loss)	2,565,927
NON-OPERATING REVENUES(EXPENSES)	
State appropriations	
Intergovernmental revenues(expenses)	
Taxes	
Use of money and property	
Gain on disposal of fixed assets	
Loss on disposal of fixed assets	
Federal grants	
Interest expense	
Other revenue	1,173,932
Other expense	
Total non-operating revenues(expenses)	1,173,932
Income(loss) before contributions and transfers	3,739,859
Capital contributions	
Extraordinary item - Loss on impairment of capital assets	
Transfers in	
Transfers out	
Change in net assets	3,739,859
Total net assets beginning	36,918,255
Total net assets - ending	\$ <u>40,658,114</u>

The accompanying notes are an integral part of this financial statement.

Statement B

STATE OF LOUISIANA LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCE CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER STATEMENT OF ACTIVITIES FOR THE YEAR ENDED JUNE 30, 2007

	Program Revenues				Net (Expense)
Expenses	Charges for Services	Operating Grants and Contributions	Capital Grants and Contributions	. <u>-</u>	Revenue and Changes in Net Assets
Entity \$ 15,913,726 \$	s\$	18,411,563_\$.\$_	2,497,837
General revenues:					
Taxes					
State appropriations					
Grants and contributions not	restricted to spe	ecific programs			
Interest		·		_	1,168,157
Miscellaneous					-
Special items				_	73,865
Extraordinary item - Loss on impa	airment of capita	al assets		_	
Transfers					
Total general revenues, spec	ial items, and tr	ansfers		_	1,242,022
Change in net assets					3,739,859
Net assets - beginning as restated	d			-	36,918,255
Net assets - ending				\$_	40,658,114

The accompanying notes are an integral part of this statement.

STATE OF LOUISIANA LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCE CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER STATEMENT OF CASH FLOWS FOR THE YEAR ENDED JUNE 30, 2007

Cash flows from operating activities		
Cash received from customers (Grants)	\$ 30,572,057	
Cash payments to suppliers for goods and services	(13,705,363)	
Cash payments to employees for services	(251,937)	
Payments in lieu of taxes	(2011)	
Internal activity-payments to other funds		
Claims paid to outsiders		
Other operating revenues(expenses)	920,797	
Net cash provided(used) by operating activities	320,191	17,535,554
		17,533,534
Cash flows from non-capital financing activities		
State appropriations		
Proceeds from sale of bonds		
Principal paid on bonds		
Interest paid on bond maturities		
Proceeds from issuance of notes payable		
Principal paid on notes payable		
Interest paid on notes payable		
Operating grants received		
Transfers in		
Transfers out		
Other		
Net cash provided(used) by non-capital financing activities		
Cash flows from capital and related financing activities		
Proceeds from sale of bonds		
Principal paid on bonds		
Interest paid on bond maturities		
Proceeds from issuance of notes payable		
Principal paid on notes payable		
Interest paid on notes payable		
Acquisition/construction of capital assets	(1,310,143)	
Proceeds from sale of capital assets	(1,0.0,1-0)	
Capital contributions		
Other		
Net cash provided(used) by capital and related financing		
activities		(1,310,143)
		(1,010,140)
Cash flows from investing activities		
Purchases of investment securities	(10,306,171)	
Proceeds from sale of investment securities		
Interest and dividends earned on investment securities	306,171	
Net cash provided (used) by investing activities		(10,000,000)
Net increase(decrease) in cash and cash equivalents		6,225,411
Cash and cash equivalents at beginning of year		16,517,899
Cash and cash equivalents at end of year	;	\$ 22,743,310

Statement D (continued)

STATE OF LOUISIANA LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCE CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED JUNE 30, 2007

Reconciliation of operating income(loss) to net cash provided(used) by operating activities:

Operating income(loss)		\$	3,418,634
Adjustments to reconcile operating income(loss) t Depreciation/amortization Provision for uncollectible accounts Other	o net cash — —	431,834	
Changes in assets and liabilities: (Increase)decrease in accounts receivable, net (Increase)decrease in due from other funds (Increase)decrease in prepayments (Increase)decrease in inventories		11,549,214	
(Increase)decrease in other assets Increase(decrease) in accounts payable and accr Increase(decrease) in compensated absences pa Increase(decrease) in due to other funds Increase(decrease) in deferred revenues Increase(decrease) in other liabilities		2,135,872	
Net cash provided(used) by operating activities		\$ <u></u>	17,535,554
Schedule of noncash investing, capital, and	financing activities:	,	
Borrowing under capital lease Contributions of fixed assets Purchases of equipment on account Asset trade-ins Other (specify)	\$		
Total noncash investing, capit	tal, and		- -

The accompanying notes are an integral part of this statement.

Statement D (concluded)

INTRODUCTION

A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A summary of the Corporation's significant accounting policies consistently applied in the preparation of the accompanying financial statements follows.

1. Nature of Activities

Louisiana Cancer Research Center of L.S.U. Health Sciences Center in New Orleans/Tulane Health Sciences Center (the "Corporation") was incorporated June 7, 2002. The Corporation is a not-for-profit organization that is exempt from Income taxes under Section 501 (c) (3) of the Internal Revenue Code.

The Corporation was organized for charitable, educational and scientific purposes. The primary purpose will be to conduct and support research and promote education in the diagnosis, detection, and treatment of cancer in the pursuit of obtaining the National Center Institute designation for its members, the Louisiana State University Health Sciences Center in New Orleans, and the Tulane University Health Sciences Center.

2. Financial Statement Presentation

The Corporation's financial statements are presented in accordance with the requirements established by the Financial Accounting Standards Board (FASB) as set forth in the Statement of Financial Accounting Standards No. 117, "Financial Statements of Not-For-Profit Organizations." Accordingly, the net assets of the Corporation are reported in each of the following classes: (a) unrestricted net assets, (b) temporarily restricted net assets, and (c) permanently restricted net assets. There were no permanently restricted net assets during the year ended June 30, 2007.

Revenue Recognition

Revenues are recognized using the full accrual basis of accounting; therefore, revenues are recognized in the accounting period in which they are earned and become measurable.

Expense Recognition

Expenses are recognized on the accrual basis; therefore, expenses, including salaries, are recognized in the period incurred, if measurable.

B. BUDGETARY ACCOUNTING

The Louisiana Cancer Research Center's budget allocation is completed based on the guidelines set and/or approved by the Center's Board of Directors. The appointed officials considered the following factors and indications when setting next year's budget and budget allocations.

- Strategic needs assessments for programs and building construction must be completed due to delays, interruptions and changes caused by Hurricane Katrina and its aftermath.
- Construction of a new Cancer Center building has been delayed pending reassessment.
- Recruitment and retention of world class faculty is more difficult yet more critical in light of Hurricane Katrina; thus requiring increased investment in programs
- Meaningful and significant reductions in the number of smoking related deaths and illnesses will require substantial investment in the smoking cessation program

	API	ROPRIATIONS
Original approved budget	\$	18,411,563
Amendments:		
Final approved budget	\$	18,411,563

- C. DEPOSITS WITH FINANCIAL INSTITUTIONS AND INVESTMENTS (If all agency cash and investments are deposited in the State Treasury, disregard Note C.) See Appendix B for information related to Note C.
 - 1. DEPOSITS WITH FINANCIAL INSTITUTIONS

For reporting purposes, deposits with financial institutions include savings, demand deposits, time deposits, and certificates of deposit. Under state law the Louisiana Cancer Research Center may deposit funds within a fiscal agent bank selected and designated by the Interim Emergency Board. Further, the Louisiana Cancer Research Center may invest in time certificates of deposit in any bank domiciled or having a branch office in the state of Louisiana; in savings accounts or shares of savings and loan associations and savings banks and in share accounts and share certificate accounts of federally or state chartered credit unions.

For the purpose of the Statement of Cash Flows, all highly liquid investments (including restricted assets with a maturity of three months or less when purchased) are considered to be cash equivalents.

Deposits in bank accounts are stated at cost, which approximates market. Under state law these deposits must be secured by federal deposit insurance or the pledge of securities owned by the fiscal agent bank. The market value of the pledged securities plus the federal deposit insurance must at all times equal the amount on deposit with the fiscal agent. These pledged securities are held in the name of the pledging fiscal agent bank in a holding or custodial bank in the form of safekeeping receipts held by the State Treasurer.

GASB Statement 40, which amended GASB Statement 3, eliminated the requirement to disclose all deposits by the three categories of risk. GASB Statement 40 requires only the disclosure of deposits that are considered to be exposed to custodial credit risk. An entity's deposits are exposed to custodial credit risk if the deposit balances are either 1) uninsured and uncollateralized, 2) uninsured and collateralized with securities held by the pledging financial institution, or 3) uninsured and collateralized with securities held by the pledging financial institution's trust department or agent, but not in the entity's name.

The deposits at June 30, 2007, consisted of the following:

		<u>Cash</u>		Certificates of Deposit		Other Money Market & Repurchase Agreements		<u>Total</u>
Balance per agency books	\$_	(329,257)	\$_		\$	23,072,567	\$_	22,743,310
Deposits in bank accounts per bank	\$ _	200,000	\$_		\$	23,072,567	\$_	23,272,587
Bank balances of deposits exposed to custodial cre-	dit risk:							
a. Deposits not insured and uncollateralized	\$		\$		\$		\$_	
b. Deposits not insured and collateralized with							_	
securities held by the pledging institution.	\$_	100,000	\$_		\$	285,096	\$_	385,096
c. Deposits not insured and collateralized with			_					
securities held by the pledging institution's trust								
department or ageny but not in the entity's name.	. \$_		\$_		\$	22,713,413	\$_	22,713,413
accounts per bank" balances shown above: <u>Banking Institution</u>		Account N	lum	<u>ıber</u>		Amoun	<u>t</u>	
Whitney National Bank	715-1	12-961			\$	19.7	777	850
Whitney National Bank		12-988			*			563
3. Whitney National Bank		60-769						096
Regions National Bank	43050	90032		<u> </u>			74.	058
Total					\$	23,2	272	567
Cash in State Treasury and petty cash are in reconciling amounts reported on the better treasury and petty cash that are included Cash in State Treasury and Petty cash	alance on the	sheet to a	mc	ounts repor				
2. INVESTMENTS					_			
The Louisiana Cancer Research Center Sciences Center does/does not maintain								

Custodial Credit Risk

legal provisions authorizing investments by (BTA)).

Investments can be exposed to custodial credit risk if the securities underlying the investment are uninsured, not registered in the name of the entity, and are either held by the counterparty or the counterparty's trust department or agent but not in the entity's name. Repurchase agreements are not subject to credit risk if the

securities underlying the repurchase agreement are exempt from credit risk disclosure.

GASB Statement 40 amended GASB Statement 3 to eliminate the requirement to disclose all investments by the three categories of risk. GASB Statement 40 requires only the separate disclosure of investments that are considered to be exposed to custodial credit risk. Those investments exposed to custodial credit risk are reported by type in one of two separate columns depending upon whether they are held by a counterparty, or held by a counterparty's trust department or agent not in the entity's name. In addition, the total reported amount and fair value columns still must be reported for total investments regardless of exposure to custodial credit risk.

		nts Exposed al Credit Risk	All Investments Regardless of Custodial Credit Risk Exposure						
pe of Investment	Uninsured, *Unregistered, and Held by <u>Counterparty</u>	Uninsured, "Unregistered, and Held by Counterparty's Trust Dept. or Agent Not in Entity's Name	Reported Amount Per Balance <u>Sheet</u>	Fair <u>Value</u>					
purchase agreements	\$	\$	\$	\$					
S. Government securities S. Agency Obligations ammon & preferred stock			4,494,160	4,494,160					
ommercial paper orporate bonds			5,827,066	5,827,066					
her: (identify)									
		<u> </u>							
tal investments ınregistered - not registered in tl		- ` 	\$ 10,321,226	\$ <u>10,321,226</u>					
DERIVATIVES	,5 (1								
The institution does to risk from the credit risk		follows:		ent policy. Accordin					
Technical Bulletin 2003-1 r	equires certain note f Net Assets. See a below, if applicable	Appendix B for m	lerivatives that a ore details and	are not reported at disclose any of th					

4.

RISK DISCLOSURES

CREDIT RISK, INTEREST RATE RISK, CONCENTRATION OF CREDIT RISK, AND FOREIGN CURRENCY

A. Credit Risk of Debt Investments

Disclose the credit risk of debt investments by credit quality ratings as described by rating agencies as of the fiscal year end, including the rating agency used (Moody's, S&P, etc.). All debt investments regardless of type can be aggregated by credit quality rating (if any are un-rated, disclose that amount).

Rating Agency	Rating		Fair Value
S&P		. \$	4,494,160
		_	
		_	
	Total	\$_	4,494,160

- B. Interest Rate Risk of Debt Investments
- 1. Disclose the interest rate risk of debt investments by listing the investment type, total fair value, and breakdown of maturity in years for each debt investment type. (Note This is the prescribed method, segmented time distribution, for the CAFR. Also, total debt investments reported in this table should equal total debt investments reported in Section A Credit Risk of Debt Investments.)

•				li	in'	vestment Matu	ritie	s (in Years)	
Type of Debt Investment		Fair Value		Less Than 1		1 - 5		6 - 10	Greater Than 10
U.S. Government obligations U.S. Agency obligations U.S. Treasury obligations Mortgage backed securities Collateralized mortgage obligations Corporate bonds Other bonds Mutual bond funds Other	\$	4,494,160	\$	\$ 4,494,160				\$	
Total debt investments	\$_	4,494,160	\$	4,494,160	\$	· • ·	\$	<u> </u>	•

2. List the fair value and terms of any debt investments that are highly sensitive to changes in interest rates due to the terms (e.g. coupon multipliers, reset dates, etc.) of the investment.

Debt Investment	Fair Value	<u>lerms</u>
NONE	\$ <u> </u>	
Total	\$ <u></u>	

C. Concentration of Credit Risk

List, by amount and issuer, investments in any one issuer that represents 5% or more of total external investments (not including U.S. government securities, mutual funds, and investment pools).

	<u>uer</u>		<u>Amount</u>	% of Total Investments	
<u>NC</u>	ONE	\$			
To	tal	\$		•	
D.	Foreign Currency Risk		•		
(dej				ents that are exposed to foreign ist by currency denomination are	
<u>Fo</u>	reign Currency		Fair Va Bonds	ilue in U.S. Dollars Stocks	
NC	ONE	\$		\$	
_					
_					
To	tal .	\$		· \$	
POI	LICIES	•			
inve no p	estments, concentration of policy exists concerning th	' credit risk, intere e risks disclosed,	est rate risk, and please state tha		in this n
	io formal policy exists.			<u></u>	
	HER DISCLOSURES REC	}UIRED FOR INV	ESTMENTS		
				nutual funds_N/A	
OTI	HER DISCLOSURES REC	anaged by other g	overnments or n	nutual funds_ <u>N/A</u>	
OTI	HER DISCLOSURES REC	anaged by other g	overnments or n	Α	

STATE OF LOUISIANA LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCE CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER

Notes to the Financial Statement

As of and for the year ended June 30, 2007

	Carrying amount and market value at June 3	0 of securities to be resold <u>N/A</u>
	Description of the terms of the agreement	NA
e.	Losses during the year due to default by counterpart	artles to deposit or investment transactions <u>NONE</u>
f.	Amounts recovered from prior-period losses whi	ch are not shown separately on the balance sheet
<u>Leg</u>	egal or Contractual Provisions for Reverse Repurchase	Agreements
g.	Source of legal or contractual authorization for use	of reverse repurchase agreements N/A
h.	a normal decima that came NONE	rovisions for reverse repurchase agreements that
Rev	everse Repurchase Agreements as of Year-End	
i.	outstanding at year end, that is, the aggregate a	eements (other than yield maintenance agreements) mount of reverse repurchase agreement obligations te market value of the securities underlying those
j.	Commitments on June 30, 2007 to repurchase sec	curities under yield maintenance agreements
k.	Market value on June 30, 2007 of the secu	rities to be repurchased N/A
I.	Description of the terms of the agreements to repu	rchase <u>N/A</u>
m.	. Losses recognized during the year due to default NONE	by counterparties to reverse repurchase agreements
n.	Amounts recovered from prior-period losses was statement NONE	hich are not separately shown on the operating
Fair	air Value Disclosures	
0.		timate fair value of investments, if fair value is not ed upon quoted market prices
p.	Basis for determining which investments, if any, ar	e reported at amortized cost N/A
q.	For investments in external investment pools that regulatory oversight for the poolNA	t are not SEC-registered, a brief description of any

	Any involuntary participation in an external investment pool <u>NONE</u>
i	if you are unable to obtain information from a pool sponsor to determine the fair value of y investment in the pool, methods used and significant assumptions made in determining fair value at the reasons for having had to make such an estimate <u>N/A</u>
-	

D. CAPITAL ASSETS - INCLUDING CAPITAL LEASE ASSETS

The fixed assets used in the Special Purpose Government Engaged only in Business-Type Activities are included on the balance sheet of the entity and are capitalized at cost. Depreciation of all exhaustible fixed assets used by the entity is charged as an expense against operations. Accumulated depreciation is reported on the balance sheet. Depreciation for financial reporting purposes is computed by the straight line method over the useful lives of the assets.

	٠			Year e	ended June 30,	2007		
	-		Prior	Adjusted				<u> </u>
		Balance	Period	Balance				Balance
	_	6/30/2006	Adjustment	7/1/2008	Additions	Transfers*	Retirements	6/30/2007
Capital assets not being depreciated		•						
Land	\$	671,808	\$ \$	671,808 \$	\$		\$ \$	671,808
Non-depreciable land improvements Capitalized collections				- -				- -
Construction in progress	_	2,410,253		2,410,253		477,582		2,887,835
Total capital assets not being								
depreciated	\$_	3,082,061	\$\$	3,082,061 \$	{	477,582	\$ <u> </u>	3,559,643
Other capital assets								
Furniture, fixtures, and equipment	\$	2,922,919	\$ \$	2,922,919 \$	832,562 \$;	\$ \$	3,755,481
Less accumulated depreciation		(587,447)		(587,447)	(431,835)			(1,019,282)
Total furniture, fixtures, and equipment	_	2,335,472		2,335,472	400,727			2,736,199
Buildings and improvements				_				-
Less accumulated depreciation								
Total buildings and improvements	_							
Depreciable land improvements				_				-
Less accumulated depreciation	_							
Total depreciable land improvements	-	_						
Infrastructure				_				-
Less accumulated depreciation	_							
Total infrastructure	_				- ,	-		
Total other capital assets	\$_	2,335,472	\$\$	2,335,472 \$	400,727	_	\$\$	2,736,199
Capital Asset Summary:								
Capital assets not being depreciated	\$	3,082,061	\$ - \$	3,082,061 \$	- \$	477,582	\$ - \$	3,559,643
Other capital assets, at cost	_	2,922,919	_	2,922,919	832,562			3,755,481
Total cost of capital assets		6,004,980		6,004,980	832,562	477,582		7,315,124
Less accumulated depreciation	-	(587,447)		(587,447)	(431,835)			(1,019,282)
Capital assets, net	\$_	5,417,533	\$\$	5,417,533 \$	400,727 \$	477,582	\$\$	6,295,842

Should be used only for those completed projects coming out of construction-in-progress to fixed assets; not associated with transfers reported elsewhere in this packet.

E. INVENTORIES - N/A

F. RESTRICTED ASSETS - N/A

G. LEAVE

COMPENSATED ABSENCES

The Louisiana Cancer Research Center has the following policy on annual and sick leave:

Employees of the center accrue leave immediately upon hire, but at varying rates based on classification and years of service. Vacation and sick time are accrued on a monthly basis. Upon termination, employees will be paid for accrued vacation leave to be calculated at the employee's hourly rate upon termination. Accrued annual and sick leave at June 30, 2007 amounted to \$40,985.

2. COMPENSATORY LEAVE - N/A

H. RETIREMENT SYSTEM

All full-time Louisiana Cancer Research Center employees are eligible to participate in the 403(b) retirement plan. The existing 403(b) plan is a tax-sheltered annulty (TSA) plan, currently administered by TIAA-CREF. Although eligible employees are not required to participate in the plan, contributions are made by the Center as part of the established benefits package. The plan allows for employee contributions, with a matching requirement of up to 3% of the employee's annual compensation. The Center's matching contribution amounted to \$32,252 for the year ended June 30, 2007.

- 1. POST RETIREMENT HEALTH CARE AND LIFE INSURANCE BENEFITS N/A
- J. LEASES N/A
- K. LONG-TERM LIABILITIES N/A
- L. CONTINGENT LIABILITIES N/A
- M. RELATED PARTY TRANSACTIONS

Louisiana Gene Therapy Research Consortium

The Louisiana Cancer Research Center of LSU Health Sciences Center in New Orleans/Tulane Health Sciences Center (the "Center") and the Louisiana Gene Therapy Research Center (LGTRC) have an affiliate relationship as they are both partnerships between the LSU Health Sciences Center in New Orleans and the Tulane Health Sciences Center. LGTRC includes both LSU Health Sciences Center in New Orleans and in Shreveport and Tulane Health Sciences Center as partners while the Center includes only L.S.U. Health Sciences Center in New Orleans and Tulane University Health Sciences Center, which are governed by governing boards with common members.

The Center has an arrangement with the LGTRC that allows for resource cost sharing. The Center and LGTRC share office space, personnel, and other related supplies and services. Overhead expenses are captured in a cost (common cost) pool and allocated to the appropriate organization based on space, usage, and "percent of effort" where applicable. LGTRC pays all shared expenses on behalf of the Center's research and cessation components. The Center reimburses LGTRC based on billings. The total billed to the Center for the fiscal year ended June 30, 2007 was \$384,038.

LSU Health Sciences Center in New Orleans

LSU Health Sciences Center in New Orleans is one of the two partner institutions that comprise the Center. The other institution is Tulane University Health Sciences Center.

LSU Health Sciences Center in New Orleans (Continued)

As management, two members of the LSU Health Sciences Center in New Orleans are on the governing board of the Center. The Chancellor of LSU Health Sciences Center in New Orleans is currently the Chair of the Center (the position rotates annually between the Chancellor of LSU Health Sciences Center and the Senior Vice President for Tulane Health Sciences Center, as dictated by statute). The Senior Vice President for Tulane Health Sciences Center was chair for Fiscal Year 2007. The Vice Chancellor for Academic Affairs of LSU Health Sciences Center in New Orleans is also a voting member of the Center's Board.

As transferring agent of state funding support, LSU Health Sciences Center in New Orleans (an entity of the State) is the transferring agency on behalf of the State. Under a Cooperative Endeavor Agreement arrangement, it is responsible for transferring funds appropriated by the State of Louisiana for the Center.

As grantee, the LSU Health Sciences Center in New Orleans is allocated the Center funding support for program development (part of the mission of the Center). Transfer of funds to LSU Health Sciences Center in New Orleans for the program is governed by a fully executed operating agreement which includes an annual budget submitted by LSU Health Sciences Center in New Orleans and approved by the Center's Board. The total amount billed to the Center for services rendered during the fiscal year ended June 30, 2007 was \$3,706,402.

As a vendor, LSU Health Sciences Center Auxiliary Stores provide goods and services (including research equipment, office and computer supplies) to the Center. The stores conveniently provide products and services which support the mission of the Center. The total amount billed to the Center for goods and services during the fiscal year ended June 30, 2007 was \$131,926.

Tuiane University Health Sciences Center

Tulane University Health Sciences Center (TUHSC) is one of the two partner institutions that comprise the Center. The other institution is LSU Health Sciences Center in New Orleans.

As management, two members of the Tulane University Health Sciences Center are on the governing board of the Center. TUHSC's Senior Vice President (currently Vice-Chair of the Center) and Associate Senior Vice President for Health Sciences are voting members of the Center's Board.

As grantee, TUHSC is allocated Center funding support for program development (part of the mission of the Center). Transfer of funds to TUHSC for the program is governed by a fully executed operating agreement which includes an annual budget submitted by TUHSC and approved by the Center's Board. The total amount billed to the Center for services rendered during the fiscal year ended June 30, 2007 was \$4,150,489.

- N. ACCOUNTING CHANGES N/A
- IN-KIND CONTRIBUTIONS N/A
- P. DEFEASED ISSUES N/A
- Q. COOPERATIVE ENDEAVORS SEE SCHEDULE 16
- R. GOVERNMENT-MANDATED NONEXCHANGE TRANSACTIONS (GRANTS) N/A
- S. VIOLATIONS OF FINANCE-RELATED LEGAL OR CONTRACTUAL PROVISIONS N/A
- T. SHORT-TERM DEBT N/A
- U. DISAGGREGATION OF RECEIVABLE BALANCES

Receivables at June 30, 2007, were as follows:

Activíty		Customer (Grant) Receivables		Taxes	Receivables from other Governments	_	Other Receivables	Total Receivables
Cancer Research Program	s_	2,736,163	\$	<u> </u>		\$	9,840 \$	2,746,003
Cessation Program		1,866,728				_	654,000	2,520,728
Fund Raising			_			_		
Gross receivables Less allowance for uncollectible accounts	\$_	4,602,891	\$_	\$		_\$	663,840 \$	5,266,731
Receivables, net	\$_	4,602,891	\$_	- \$	-	_ \$	663,840 \$	5,266,731

V. DISAGGREGATION OF PAYABLE BALANCES

Payables at June 30, 2007, were as follows:

			Salaries				
			and	Accrued		Other	Total
Activity		Vendors	Benefits	Interest		Payables	Payables
Cancer Research Program		2,209,193 \$		<u> </u>	- \$_	40,985 \$	2,250,178
Cessation Program		1,718,817					1,718,817
Fund Raising							
Total payables	\$_	3,928,010 \$		<u> </u>	\$ _	40,985 \$	3,968,995

- W. SUBSEQUENT EVENTS N/A
- X. SEGMENT INFORMATION N/A
- Y. DUE TO/DUE FROM AND TRANSFERS N/A
- Z. LIABILITIES PAYABLE FROM RESTRICTED ASSETS N/A
- AA. PRIOR-YEAR RESTATEMENT OF NET ASSETS N/A
- BB. NET ASSETS RESTRICTED BY ENABLING LEGISLATION (GASB STATEMENT 46) N/A
- CC. IMPAIRMENT OF CAPITAL ASSETS N/A

DD. EMPLOYEE TERMINATION BENEFITS

Termination benefits are benefits, other than salarles and wages, that are provided by employers as settlement for involuntary terminations initiated by management, or as an incentive for voluntary terminations initiated by employees. Involuntary termination benefits include benefits such as payment for unused leave balances. Voluntary termination benefits include benefits such as enhanced early retirement options resulting from an approved early retirement plan and payment for unused leave balances.

Other termination benefits may include:

- 1. Early retirement incentives, such as cash payments, enhancement to defined benefit formula
- 2. Health care coverage when none would otherwise be provided (COBRA)
- 3. Compensated absences, including payments for leave balances
- 4. Payments due to early release from employment contracts

GASB 47 requires the following disclosures about an employer's accounting for employee termination benefits:

- 1. A description of the termination benefit arrangement(s)
- 2. Period the employer becomes obligated
- 3. Number of employees affected
- 4. Cost of termination benefits
- 5. Type of benefit(s) provided
- 6. The period of time over which the benefits are expected to be provided
- 7. If the termination benefit affects the defined benefit pension (OPEB) obligations, disclose the change in the actuarial accrued liability for the pension or OPEB plan attributable to the termination benefit
- 8. When termination liabilities are reported, disclose the significant methods and assumptions used to determine the liabilities to be disclosed (for as long as the liability is reported)

Substantially all employees are eligible for termination benefits upon separation from the state. The agency recognizes the cost of providing these benefits as expenditures when paid during the year. For 2007, the cost of providing those benefits for 0 voluntary terminations totaled \$0. For 2007, the cost of providing those benefits for 0 involuntary terminations totaled \$0.

The liability for the accrued voluntary terminations benefits payable at June 30, 2007 is \$0. This liability consists of 0. The liability for the accrued involuntary terminations benefits payable at June 30, 2007 is \$ 0. This liability consists of 0 involuntary terminations.

If a termination benefit is not recognized because the expected benefits are not estimable, the employer should disclose that fact. Briefly describe termination benefits provided to employees as discussed above. If none, please state that fact.

The Louisiana Cancer Research Center compensates employees for accrued vacation leave balances upon voluntary or involuntary termination. Although employees can continue to access health benefits under COBRA, the entire premium is paid by the employee if he/she wishes to continue coverage. There are no other termination benefits provided by the Louisiana Cancer Research Center.

A terminated employee can continue to access health benefits, however, if the COBRA participant is paying the ENTIRE premium then there is no state contribution on behalf of this individual. Therefore, when a terminated employee pays 100% of the premium, the state would not have a termination liability.

STATE OF LOUISIANA LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCE CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER

SCHEDULE OF PER DIEM PAID TO BOARD MEMBERS For the Year Ended June 30,2007

<u>Name</u>		Amount
NONE	\$	
	,	
	•	
	•	
	•	
	1	
	•	
)	
	l	
	` \$	

Note: The per diem payments are authorized by Louisiana Revised Statute, and are presented in compliance with House Concurrent Resolution No. 54 of the 1979 Session of the Legislature.

SCHEDULE 1

STATE OF LOUISIANA LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCE CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER SCHEDULE OF NOTES PAYABLE June 30, 2007

Issue	Date of Issue	Original Issue	Principal Outstanding 6/30/PY	Redeemed (Issued)	Principal Outstanding 6/30/CY	Interest Rates	Interest Outstanding 6/30/CY
NONE		\$	\$	\$	\$		\$
				***************************************			***************************************
			· · · · · · · · · · · · · · · · · · ·	·····			-
		<u></u>	The second secon				
			· · · · · · · · · · · · · · · · · · ·				
		<u></u>		· · · · · · · · · · · · · · · · · · ·			
						<u></u>	<u>- u</u>
· · · · · ·							
Total		\$	\$	\$	\$		<u> </u>

^{*}Send copies of new amortization schedules

SCHEDULE 3-A

STATE OF LOUISIANA LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCE CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER SCHEDULE OF BONDS PAYABLE June 30, 2007

issue	Date of Issue	Original Issue	Principal Outstanding 6/30/PY	Redeemed (lssued)	Principal Outstanding 6/30/CY	Interest Rates	Interest Outstanding 6/30/CY
NONE	·	\$	\$	\$	\$·		\$.
		•		-			
				<u></u>			
					.		
	·						
					· · · · ·		
<u></u>				· <u>·············</u>			
				***************************************	<u></u>		
						4	

Total		\$	\$	\$	\$		\$

^{*}Send copies of new amortization schedules

STATE OF LOUISIANA LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCE CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER SCHEDULE OF CAPITAL LEASE AMORTIZATION For The Year Ended June 30, 2007

Fiscal Year Ending:	<u>Payment</u>	<u>Interest</u>	<u>Principal</u>	Balance
2008	\$ NONE	\$	\$	\$
2009				
2010				
2011				
2012				
2013-2017				to the
2018-2022		4		
2023-2027				
2028-2032				
Total	\$	\$	\$	\$

STATE OF LOUISIANA LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCE CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER SCHEDULE OF NOTES PAYABLE AMORTIZATION For the Year Ended June 30, 2007

Fiscal Year Ending:	<u>Principal</u>	Interest
2008	\$ <u>NONE</u>	\$
2009		
2010		
2011		
2012		
2013-2017		
2018-2022		
2023-2027		
2028-2032		
Total	\$	\$

STATE OF LOUISIANA LOUISIANA CANCER RESEARCH CENTER OF L.S.U. HEALTH SCIENCE CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER SCHEDULE OF BONDS PAYABLE AMORTIZATION For The Year Ended June 30, 2007

Fiscal Year Ending:		<u>Principal</u>		<u>Interest</u>
2008	\$_	NONE	\$	
2009	_			
2010			•	
2011	_			
2012	_			
2013	_	<u>.</u>		
2014				
2015	-			
2016	_			
2017				
2018	_			
2019	_			
2020	_			
2021		· · · · · · · · · · · · · · · · · · ·		
2022	-			
2023	_			
2024				
2025	_			
2026	_			
2027				
2028				
2029	_	<u>-</u>		
2030				
2031	_			
2032	***			
Total	\$		\$	

SCHEDULE 4-C

STATE OF LOUISIANA

LOUISIANA CANCER RESEARCH CENTER OF L.S.U HEALTH SCIENCE CENTER IN NEW ORLEANS/TULANE HEALTH SCIENCES CENTER

COMPARISON FIGURES

To assist OSRAP in determining the reason for the change in financial position for the State, please complete the schedule below. If the change is greater than \$1 million, explain the reason for the change.

			2007		2006		Difference		Percentage <u>Change</u>
1)	Revenues	\$_	19,953,585	_\$_	17,252,637	_\$	2,700,948	\$.	16%
	Expenses	_	15,913,726		14,037,663		1,876,063		13%
2)	Capital assets	_	6,295,842		5,417,553		878,289		16%
•	Long-term debt						-		
	Net Assets	_	40,658,114		36,918,255		3,739,859		10%

Explanation for change:

Revenues increased by 16% because tobacco tax collections increased for fiscal year 2007. Also, interest income for the Center increased significantly due to rising short term interest rates and other more diversified investment strategies.

Expenses increased by 13% due to increased cancer research activities. Four new faculty members were recruited and funded this fiscal year.

Net assets increased by 10% primarily due to the overall increase in revenue from tobacco tax collections (state grant) and interest income.

SCHEDULE 16 - COOPERATIVE ENDEAVORS FOR YEAR ENDED JUNE 30, 2007

AGENCY	NAME
AGENCY	NUMBER

Contract Financial	Parties	Brief Description	Multi-year, One-Time,	Funding Source per Coop Agreement based on Net Liability as of June 30, 2007						
Management	to the	of the	or Other	100%	100%	100%	100%	100%	100%	
System #	Coop	Соор	Appropriation	State	SGR	Stat. Ded.	G.O. Bonds	Federal	IAT	
NONE										
							•			
		·								
				,					<u> </u>	
			<u></u>							
						<u></u>	· ·			
						-				
	·									
					·					
·										
			•							
		ļ								
		TOTAL		0.00	0.00	0.00	0.50	0.00	0.1	
		TOTAL		0.00	0.00	0.00	0.00	0.0	00	

SCHEDULE 16